14 research outputs found
The measure of effectiveness of a short-term 2-week intensive Cardiac Rehabilitation program in decreasing levels of anxiety and depression
No full textResearch on heart disease have found a strong and consistent evidence of association between some psychosocial risk factors, including depression, anxiety, self-efficacy, lack of social support and outcome of disease. Depression increases the risk of cardiac death and is highly predictive of reduced adherence to recommended treatments; anxiety appears to be linked to adverse cardiac outcomes. It was demonstrated that Cardiac Rehabilitation (CR) leads to substantial improvements and positive outcomes because combines the prescription of physical activity with the modification of risk factors and aims to reduce symptoms related to the disease and the risk of new cardiovascular events. The main objective of this study is to determine if a short and intense CR program can produce a positive impact on anxious and depressive symptoms revealed in cardiac patients, confirming results of previous researches. The protocol was proposed to all patients referred for an outpatient CR after an acute event who attended the short 2-week intensive rehabilitation program. A total of 157 patients recruited at the operating unit of Cardiology, in the Hospital of Cittadella (Italy), was included in the analysis. The Beck Depression Inventory-II and the State-Trait Anxiety Inventory-Y were administered to the patients. SPSS 17.0 was used for statistical analysis. T-tests for paired samples were used to evaluate differences between the beginning and the end of the CR program. There was a statistically significant difference between the beginning and the end of the CR program. Results for paired samples showed significant differences in all factors of the BDI-II and in the total score. In addition, a statistically significant difference was found even in the state - anxiety subscale. No significant difference was detected for the trait anxiety. According to recent studies, this research shows that the CR program has a significant impact on levels of anxiety and depression, because all activities focus their commitment on changing the patient’s personal beliefs and perception of illness, promoting the exchange of information and sharing of concerns and fears, increasing the patient’s resilience with the aim of enabling him/her to reorganize positively his/her personal, family and professional sphere.</jats:p
The positive impact of a four-week Cardiac Rehabilitation program on depression levels of cardiological patients
No full textStructured multidisciplinary discussion of HRCT scans for IPF/UIP diagnosis may result in indefinite outcomes
No full textRecent ATS/ERS/JRS/ALAT guidelines for the diagnosis and management of Idiopathic Pulmonary Fibrosis (IPF) have defined key features and specific high-resolution computerized tomography (HRCT) patterns for the diagnosis of UIP. The aim is the sorting of patients with suspected IPF into three subgroups, confident, possible or inconsistent with UIP patterns, after a multidisciplinary discussion (MDD). Specialists in respiratory diseases, radiologists and pathologists should reach IPF diagnosis based on either patients' clinical, radiological and laboratory data, either submitting patients to surgical biopsy. After ATS/ERS/JRS/ALAT recommendations have been applied, it has been identified a subgroup of patients showing uniform apical-basal distribution of honeycombing and reticular abnormalities that could not be categorized as confident, or possible nor inconsistent with UIP. These patients were subsequently diagnosed with IPF after MDD and lung biopsy. Inclusion of this pattern in the recommendation for IPF diagnosis would be worth considering
The positive impact of a four-week Cardiac Rehabilitation program on depression levels of cardiological patients
No full textMyosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
No full textBackground & Aims: Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period. Methods: We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation. Results: At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted sub-hazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99–1.86, p = 0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted sub-hazard ratio 1.18, 95% CI 1.04–1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p = 0.018) and those with isolated sarcopenia (p = 0.046) than in patients without muscle changes. Lastly, we found a strong correlation of function tests and frailty scores with the presence of muscle changes. Conclusions: Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis. Impact and implications: This study investigates the prognostic role of muscle changes in patients with cirrhosis. The novelty of this study is its multicentre, prospective nature and the fact that it distinguishes between the impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may play a dominant role in the prognosis of patients with cirrhosis
Differential Impact of Tumor Endothelial Angiopoietin-2 and Podoplanin in Lymphatic Endothelial Cells on HCC Outcomes with Tyrosine Kinase Inhibitor Treatment According to Sex
No full textHepatocellular carcinoma (HCC) is the second leading cause of cancer death worldwide. Curative treatments are available to a minority of patients, as HCC is often diagnosed at an advanced stage. For patients with unresectable and multifocal HCC, tyrosine kinase inhibitor drugs (TKIs) are the only potential treatment option. Despite extensive research, predictors of response to these therapies remain elusive. This study aimed to analyze the biological and histopathological characteristics of HCC patients treated with TKIs, focusing on angiogenesis and lymphangiogenesis. Immunohistochemistry quantified the expression of angiopoietin-2 (Ang2), lymphatic endothelial cells (LEC) podoplanin, and C-type Lectin Domain Family 2 (CLEC-2), key factors in neoangiogenesis and lymphangiogenesis. An increased expression of endothelial Ang2 and LEC podoplanin predicted a lower risk of metastasis. Female patients had significantly longer overall survival and survival on TKIs, associated with higher tumor expression of endothelial Ang2 and LEC podoplanin. Moreover, LEC podoplanin expression and a longer time on TKIs were independently correlated with improved survival on TKI therapy at Cox regression analysis. These findings suggest that endothelial Ang2 and LEC podoplanin could be potential biomarkers for predicting treatment outcomes and guiding therapeutic strategies in HCC patients treated with TKIs
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis
No full textBACKGROUND AND AIM
Sarcopenia and myosteatosis are common in patients with cirrhosis. This study aimed to determine the prevalence of these muscle changes, their interrelations and their prognostic impact over a 12-month period.
METHODS
We conducted a prospective multicentre study involving 433 patients. Sarcopenia and myosteatosis were evaluated using computed tomography scans. The 1-year cumulative incidence of relevant events was assessed by competing risk analysis. We used a Fine-Gray model adjusted for known prognostic factors, to evaluate the impact of sarcopenia and myosteatosis on mortality, hospitalization, and liver decompensation.
RESULTS
At enrolment, 166 patients presented with isolated myosteatosis, 36 with isolated sarcopenia, 135 with combined sarcopenia and myosteatosis and 96 patients showed no muscle changes. The 1-year cumulative incidence of death in patients with either sarcopenia and myosteatosis (13.8%) or isolated myosteatosis (13.4%) was over twice that of patients without muscle changes (5.2%) or with isolated sarcopenia (5.6%). The adjusted subhazard ratio for death in patients with muscle changes was 1.36 (95% CI 0.99, 1.86) (P=0.058). The cumulative incidence of hospitalization was significantly higher in patients with combined sarcopenia and myosteatosis than in patients without muscle changes (adjusted subhazard ratio 1.18, 95% CI 1.04 to 1.35). The cumulative incidence of liver decompensation was greater in patients with combined sarcopenia and myosteatosis (p=0.018) and those with isolated sarcopenia (p=0.046) than in patients without muscle changes. Lastly, we found a strong correlation between function tests and frailty scores with the presence of muscle changes.
CONCLUSIONS
Myosteatosis, whether alone or combined with sarcopenia, is highly prevalent in patients with cirrhosis and is associated with significantly worse outcomes. The prognostic role of sarcopenia should always be evaluated in relation to the presence of myosteatosis.
Impact and implications
This study investigates the prognostic role of muscle changes in patients with liver cirrhosis. The novelty of this study is the multicentre, prospective nature and the distinguishing impact of individual muscle changes and their combination on prognosis in cirrhosis. This study highlights the prognostic role of myosteatosis, especially when combined with sarcopenia. On the other hand, the relevance of sarcopenia could be mitigated when considered together with myosteatosis. The implication from these findings is that sarcopenia should never be evaluated individually and that myosteatosis may have a dominant role in the prognosis of patients with liver cirrhosis
Clinical characteristics and outcomes of vaccinated patients hospitalised with SARS-CoV-2 breakthrough infection: Multi-IPV, a multicentre study in Northern Italy
No full textBackground: Despite the well-known efficacy of anti-COVID-19 vaccines in preventing morbidity and mortality, several vaccinated individuals are diagnosed with SARS-CoV-2 breakthrough infection, which might require hospitalisation. This multicentre, observational, and retrospective study aimed to investigate the clinical characteristics and outcomes of vaccinated vs. non -vaccinated patients, both hospitalised with SARS-CoV-2 infection in 3 major hospitals in Northern Italy. Methods: Data collection was retrospective, and paper and electronic medical records of adult patients with a diagnosed SARS-CoV-2 infection were pseudo-anonymised and analysed. Vaccinated and non -vaccinated individuals were manually paired, using a predetermined matching criterion (similar age, gender, and date of hospitalisation). Demographic, clinical, treatment, and outcome data were compared between groups differing by vaccination status using Pearson's Chi-square and Mann -Whitney tests. Moreover, multiple logistic regression analyses were performed to assess the impact of vaccination status on ICU admission or intra-hospital mortality. Results: Data from 360 patients were collected. Vaccinated patients presented with a higher prevalence of relevant comorbidities, like kidney replacement therapy or haematological malignancy, despite a milder clinical presentation at the first evaluation. Non -vaccinated patients required intensive care more often than their vaccinated counterparts (8.8% vs. 1.7%, p = 0.002). Contrariwise, no difference in intra-hospital mortality was observed between the two groups (19% vs. 20%, p = 0.853). These results were confirmed by multivariable logistic regressions, which showed that vaccination was significantly associated with decreased risk of ICU admission (aOR=0.172, 95%CI: 0.039-0.542, p = 0.007), but not of intra-hospital mortality (aOR=0.996, 95%CI: 0.582-1.703, p = 0.987). Conclusions: This study provides real -world data on vaccinated patients hospitalised with COVID-19 in Northern Italy. Our results suggest that COVID-19 vaccination has a protective role in individuals with higher risk profiles, especially regarding the need for ICU admission. These findings contribute to our understanding of SARS-CoV-2 infection outcomes among vaccinated individuals and emphasise the importance of vaccination in preventing severe disease, particularly in those countries with lower first -booster uptake rates. (c) 2024 The Author(s). Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Cigarette smoke and human pulmonary immune responses to mycobacteria
No full textRecent epidemiological evidence suggests that up to 15% of worldwide tuberculosis (TB) cases may be attributable to tobacco smoking. The aim of the studies reported here was to gain insights into the effects of exposure to cigarette smoke on human cells that form part of the innate immune system of host defence in the lung. The experiments on the pulmonary effects of cigarette smoke confirm that exposure has a significant effect upon innate host defences. Significant reductions in the production of key cytokines implicated in defences against mycobacteria were observed, not attributable to impairment of mycobacterial uptake by cigarette smoke extract exposure. Furthermore, control of intracellular mycobacterial growth was impaired by cigarette smoke extract exposure
Oulema melanopus
No full textOulema melanopus (Linnaeus, 1758) (Figs 2, 7, 12, 17–18, 27) Chrysomela melanopus Linnaeus, 1758: 376 (original description). = Crioceris melanopoda O. F. Müller, 1776: 85 (original description). = Crioceris hordei Geoffroy, 1785 in FOURCROY (1785): 95 (original description). = Crioceris azurea Voet, 1806: 37 (unavailable name). = Lema cyanella var. atrata Waltl, 1835: 81 (original description). = Lema melanopa var. nigricans Westhoff, 1882 (original description). = Lema melanopa var. waltli Heinze, 1927 (new substitute name for atrata Waltl, 1835). Type localities. Chrysomela melanopus: ‘Europa’. Crioceris melanopoda: ‘ Denmark, Sjaelland / Føllenslev’ [neotype], not stated in original description. Crioceris hordei: ‘Paris, Montrouge’ [neotype], [‘Paris’, in original description]. Lema cyanella var. atrata: ‘Málaga, Ronda’ [neotype], [‘Andalusiens’, by the title of original description]. Lema melanopa var. nigricans: ‘Münster’ [in original description]. Type material. Chrysomela melanopus: The photographs of a lectotype (male, designated by BERTI 1989), labelled: ‘melanopus [w, h] // 105 [w, p]’ and 1 paralectotype (female), without any labels, both deposited at The Linnean Society, London, UK, are available at http://www.linnean.org/Library-and-Archives/online-collections.htm. Crioceris melanopoda: NEOTYPE (designated here): ♂, ‘ Sjaelland / Føllenslev / 18-8-1990 / H. Hendriksen [w, h] // NEOTYPUS, / Crioceris melanopoda / O. F. Müller, 1776 / des. J. Bezděk & / A. Baselga, 2014 [r, p] // Oulema / melanopus / (Linnaeus, 1758) / J. Bezděk det. 2014 [w, p]’ (ZMUC). Crioceris hordei: NEOTYPE (designated here): ♂, ‘ FRANCE, Paris, / Montrouge (14e distr.), / 28.v.2014, / J.-D. Chapelin-Viscardi leg. [w, p] // NEOTYPUS, / Crioceris hordei / Geoffroy, 1785 / des. J. Bezděk & / A. Baselga, 2014 [r, p] // Oulema / melanopus / (Linnaeus, 1758) / J. Bezděk det. 2014 [w, p]’ (MNHN). Lema cyanella var. atrata: NEOTYPE (designated here): ♂, ‘ HISPANIA Málaga Ronda / 30/05/1983 Sierra Nieves / Cortijo Quejigales / 1250m, G. Bastazo leg. [w, p] // NEOTYPUS, / Lema cyanella var. atrata / Waltl, 1835 / des. J. Bezděk & / A. Baselga, 2014 [r, p] // Oulema / melanopus / (Linnaeus, 1758) / J. Bezděk det. 2014 [w, p]’ (MNCN). Lema melanopa var. nigricans: Not examined. Not found in Westhoffʼs collection in Münster. Additional material examined. EUROPE: ALBANIA: Starova, Koritza env., 1918, 1♀, Vuillaume leg. (MNHN). AUSTRIA: NIEDERÖSTERREICH: Pitten, 25.vii.1973, 1 ♂, P. Magrini leg. (MMCM). BELGIUM: Bruxelles, 14.ix.1890, 2♂♂ (MNHN). BOSNIA AND HERZEGOVINA: Trebević Mt., v.1907, 1♂, Dr. Lokay leg.(NMPC). BULGARIA: Harmanli, 17.vii.1991, 1 ♂, V. Kubáň leg. (JBCB). CROATIA: Plitvice, 1.vi.1987, 1 ♂, Z. Malinka leg. (ZMCO). CZECH REPUBLIC: MORAVIA: Hranice-Drahotuše, 3.v.1997, 1 ♂, J. Bezděk leg. (JBCB). DENMARK: SJAELLAND: Lillerød øst, 2.v.1986, 3♂♂, H. Hendriksen leg. (ZMUC). FINLAND: ‘Finland’, 1♀ (MNHN). FRANCE: RHÔNE- ALPES: Haute-Savoie, Viry, 1 ♂, J. Hamon leg. (MNHN). GERMANY: BADEN- WÜRTTEMBERG: Leingarten, 11.x.1998, 1♂, D. Borisch leg. (NHRS). GREECE: CENTAL MACEDONIA: Litokhoro env. [= Litochoro], 28.–30.iv.1989, 1 ♂, J. Ježek leg. (NMPC). RHODOS: ‘Rhodus’, 1 ♀, Hedeburg leg. (NHRS). HUNGARY: SOMOGY: Siófok, 1 ♂, Lichtneckert leg. (HNHM). ITALY: SICILY: Ficuzza, 1 ♂, Holdhaus leg. (NHMW). TOSCANA: Gabbro, 5.vii.1990, 1 ♂, D. Sassi leg. (DSCM). MOLDOVA: Vall. du Berlad, 1 ♂ 2 ♀♀, A. L. Montandon leg. (MNHN). ROMANIA: București, 1 ♀, Montandon leg. (MNHN). RUSSIA: SAMARA: Tockoye, 1917, 2 ♀♀, Dr. Jureček leg. (NMPC). SERBIA: Kragujevac, 4.iv.1992, 1 ♀, M. Rozsíval leg. (JBCB). SLOVAKIA: Gemerský Jablonec, 4.vii.1994, 1 ♂, J. Bezděk leg. (JBCB). SLOVENIA: Litija env., Zgornji Hotič, 4.–5.vii.1999, 1 ♂, Z. Malinka leg. (ZMCO). SPAIN: ANDALUSIA: Nigüelas, 19.iv.1995, 1 ♂, P. Průdek leg. (JBCB). SWEDEN: Uppsala, 10.iv.1954, 1 ♂, O. Lundblad leg. (NHRS). SWITZERLAND: autostrada Bern, Parc Lindenerin, 23.viii.1996, 1 ♀, P. Montemurro leg. (MMCM). UNITED KINGDOM: ENGLAND: Cumbria, Silecroft, 16.viii.1980, 1 ♂, R. W. J. Read leg. (BMNH). NORTH AFRICA: MOROCCO: Pilote vill., near Khemisset, 19.v.1997, 1 ♂, P. Průdek leg. (JBCB). ASIA: GEORGIA: Sukhumi, 10.viii.1976, 1 ♀, J. Pradáč leg. (NMPC). RUSSIA: FAR EAST: Primorski kray, Lazovski zapovednik, Lazo, 1375 m, 2.vi.–3.vii.2001, 1 ♂, M. Quest leg. (BMNH). SYRIA: Slinfah env., 700–1000 m, 29.v.–3.vi.2007, 1 ♀, L. Saltini leg. (DSCM). TURKEY: ‘Anatolie’, 1888, 1 ♀, C. Delagrange leg. (NMPC). NORTH AMERICA (established): UNITED STATES: MICHIGAN: Galien, 25.vi.1963, 1 ♂ (NHRS). Differential diagnosis. See diagnosis under O. duftschmidi. Comments. Crioceris melanopoda is missing in many publications on Oulema. If present, it is mentioned without any comments under O. melanopus (e.g. BERTI 1989), or considered an unjustified emendation of O. melanopus (PETITPIERRE & ALONSO- ZARAZAGA 2000), or its synonym (RILEY et al. 2003, SCHMITT 2010). We cannot agree with BERTIʼs (1989) and PETITPIERRE & ALONSO- ZARAZAGAʼs (2000) opinions. In all previously described species MÜLLER (1776) strictly gave a reference to the description, but in Crioceris melanopoda such reference is missing. In accordance with WELTER- SCHULTES (2013) we consider Crioceris melanopoda a validly described species. The type locality of Crioceris melanopoda is not specified in the original description. BERTI (1989) mentioned ‘Hartouk’ as its type locality but her interpretation is evidently false, as she mistakenly used page number instead of serial number to find the locality name in index. In order to prevent the nomenclatorial instability in O. melanopus species group, a neotype conspecific with O. melanopus originated from Denmark where Müller lived and frequently collected is designated for Crioceris melanopoda. Crioceris hordei is listed in synonymy with O. melanopus in OLIVIER (1791, 1808), LACORDAIRE (1845), KITTEL (1883) or PETITPIERRE & ALONSO- ZARAZAGA (2000). Because neither Geoffroy’s or Fourcroy’s collection exists, its true identity is unknown. In order to prevent the nomenclatorial instability in O. melanopus species group, a neotype conspecific with O. melanopus is designated for Crioceris hordei. Crioceris azurea is an unavailable name. VOET (1806) did not consistently apply the principle of binominal nomenclature, thus his work does not meet the criteria of availability (cf. WHITE 1981, LÖBL & SMETANA 2011). The citation of ‘ azurea ’ Voet in synonymy with O. melanopus by GEMMINGER & HAROLD (1874: 3257) and KITTEL (1883) does not validate the name azurea (Art. 11.6 of ICZN). Although ‘ var. atrata ’ was described as a variety of Lema cyanella (species with completely metallic blue dorsum), there is no doubt that, due to its red pronotum, it belongs to the Oulema melanopus group. Waltlʼs collection is deposited in NHMW but the relevant type specimens were not found either there or in ZMHB where some Waltlʼs types are also deposited (Schillhammer 2013, pers. comm.; Willers 2013, pers. comm.). To prevent the instability of the O. melanopus group nomenclature, a neotype, conspecific with Oulema melanopus, is designated for Lema cyanella var. atrata. Due to the primary homonymy with Lema atrata Fabricius, 1801 (South America), a new substitute name Lema melanopa var. waltli was proposed by HEINZE (1927). WESTHOFF (1882) described Lema melanopa var. nigricans and attributed it to Suffrian. After checking all Suffrianʼs publications this taxon was not found, and in accordance with all subsequent catalogues Westhoff has to be treated as its author. The type material was not found either in Westhoffʼs collection in Münster (Terlutter 2014, pers. comm.) or in MLUH (Schneider 2014, pers. comm.). A neotype is not designated due to lack of available specimens with black elytra originated from Münster or its vicinity. Distribution. Europe: Albania (BERTI 1989, present paper), Andorra (SCHMITT 2010), Austria (SCHMITT & RÖNN 2011, present paper), Belarus (NESTEROVA 2006), Belgium (SCHMITT & RÖNN 2011, present paper), Bosnia and Herzegovina (present paper), Bulgaria (present paper), Croatia (present paper), Czech Republic (BENEDIKT 2011, present paper), Denmark (HANSEN 1994, present paper), Estonia (BUKEJS 2012), Finland (SILFVERBERG 2010, present paper), France (BERTI 1989, present paper), France (Corsica) (BERTI 1989), Germany (SCHMITT & RÖNN 2011, present paper), Greece (present paper), Greece (Rhodos) (present paper), Hungary (POZSGAI & SÁRINGER 2004, present paper), Ireland (COX 2007), Italy (SCHMITT & RÖNN 2011, present paper), Italy (Sicily) (present paper), Latvia (BUKEJS 2013), Liechtenstein (BRANDSTETTER & KAPP 1996), Lithuania (BUKEJS & FERENCA 2010), Luxembourg (SCHMITT 2010), Malta (CAMERON & CARUANA GATTO 1907), Macedonia (SCHMITT 2010), Moldova (present paper), Netherlands (WINKELMAN & BEENEN 2010), Norway (SILFVERBERG 2010), Poland (CHROBOK & BOROWIEC 1993), Portugal (SCHMITT 2010), Romania (BERTI 1989, present paper), Russia (European part) (BIENKOWSKI 2011, present paper), Serbia (present paper), Slovakia (present paper), Slovenia (present paper), Spain (BERTI 1989, present paper), Sweden (SILFVERBERG 2010, present paper), Switzerland (SCHMITT & RÖNN 2011, present paper), United Kingdom (COX 2007, present paper), Ukraine (SERGEEV 2011). North Africa: Morocco (BERTI 1989, present paper). Asia: Armenia (SCHMITT 2010), Azerbaijan (SCHMITT 2010), Georgia (present paper), Iran (BERTI 1989), Iraq (SCHMITT 2010), Israel (SCHMITT 2010), Kazakhstan (BIENKOWSKI 2011), Kyrgyzstan (BIENKOWSKI 2011), Lebanon (BERTI 1989), Russia (Far East) (MIKHAILOV & CHASHCHINA 2009, present paper), Russia (Siberia) (SCHMITT 2010), Syria (BERTI 1989, present paper), Turkey (ÖZDIKMEN & ÖZBEK 2014, present paper). North America (introduced, established): Canada (LESAGE et al. 2007), United States (WHITE 1993, present paper). MIKHAILOV & CHASHCHINA (2009) newly recorded O. melanopus from the Far East of Russia but the examination of flagellum was not explicitely noted. Correct identification of the specimens based on the shape of the flagellum was confirmed by Yuri Mikhailov (2014, pers. comm.). We did not examine any specimens from Andorra, Armenia, Azerbaijan, Luxembourg, Malta, Macedonia, Portugal, Iraq, Israel, Siberia, and Tajikistan – countries listed for O. melanopus by SCHMITT (2010). However, because O. melanopus is confirmed in adjacent countries we consider the occurrence there highly probable. On the other hand, the occurrence in the Canary Islands, Madeira Archipelago, Libya, Cyprus (SCHMITT 2010), Algeria (e.g. ROZNER & ROZNER 2013), Tunisia (e.g. MAICAN 2007) and India (Kashmir) (HUSSAIN & AHMAD 2006) should be confirmed and may refer to O. duftschmidi. Especially from the Canary Islands and North African countries (except Morocco) we examined large series of specimens of O. duftschmidi but no specimen of O. melanopus. The occurrence of O. melanopus in Afghanistan as listed by SCHMITT (2010) was very probably based on the specimens published by LOPATIN (1967) – the voucher specimens deposited in MMBC proved to be O. duftschmidi. The distribution in some eastern Palaearctic countries is unclear. SCHMITT (2010) listed O. melanopus also from China, Mongolia and Japan, but we donʼt know any published paper where the genitalia of the specimens from these countries were examined. The occurrence in Japan is doubtful, the old data on O. melanopus refer to Oulema oryzae (Kuwayama, 1931) (see KIMOTO & TAKIZAWA 1994). From Mongolia it was recorded by LOPATIN (1977) and commented by MEDVEDEV (1982) but the correct identity is unknown, as it might refer either to O. melanopus or O. duftschmidi. The same can be said for the records from China.Published as part of Bezděk, Jan & Baselga, Andrés, 2015, Revision of western Palaearctic species of the Oulema melanopus group, with description of two new species from Europe (Coleoptera: Chrysomelidae: Criocerinae), pp. 273-304 in Acta Entomologica Musei Nationalis Pragae 55 (1) on pages 286-288, DOI: 10.5281/zenodo.530369
